| NEMOLIZUMAB |
Nemluvio® |
GALDERMA AUSTRALIA PTY LTD |
Atopic dermatitis |
Jul 2025 |
Not Recommended |
| LENIOLISIB |
Joenja® |
PHARMING AUSTRALIA PTY LTD |
Activated PI3K delta syndrome (APDS) |
Jul 2025 |
Recommended |
| INCOBOTULINUMTOXINA |
Xeomin® |
MERZ AUSTRALIA PTY LTD |
Dynamic equinus foot deformity; Moderate to severe spasticity of the upper limb |
Jul 2025 |
Recommended |
| CALCIPOTRIOL WITH BETAMETHASONE |
Wynzora® |
ACTOR PHARMACEUTICALS PTY LTD |
Chronic stable plaque type psoriasis vulgaris |
Jul 2025 |
Recommended |
| VANZACAFTOR WITH TEZACAFTOR AND WITH DEUTIVACAFTOR |
Alyftrek® |
VERTEX PHARMACEUTICALS PTY LTD |
Cystic fibrosis |
Jul 2025 |
Deferred |
| TERIPARATIDE |
Ritosa |
SUN PHARMA ANZ PTY LTD |
Osteoporosis |
Jul 2025 |
Recommended |
| DURVALUMAB |
Imfinzi® |
ASTRAZENECA PTY LTD |
Small cell lung cancer |
Jul 2025 |
Recommended |
| ETANERCEPT |
Nepexto® |
MAXX PHARMA PTY LTD |
Severe active rheumatoid arthritis Severe psoriatic arthritis Ankylosing spondylitis
Severe chronic plaque psoriasis Juvenile idiopathic arthritis |
Jul 2025 |
Recommended |
| DONANEMAB |
Kisunla® |
ELI LILLY AUSTRALIA PTY LTD |
Early symptomatic Alzheimer's disease |
Jul 2025 |
Not Recommended |
| NIVOLUMAB IPILIMUMAB |
Opdivo® Yervoy® |
BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD |
Unresectable or metastatic colorectal cancer |
Jul 2025 |
Not Recommended |
| EPLERENONE |
Inspra® |
VIATRIS PTY LTD |
Heart failure |
Jul 2025 |
Deferred |
| ACALABRUTINIB |
Calquence® |
ASTRAZENECA PTY LTD |
Mantle cell lymphoma |
Jul 2025 |
Recommended |
| CABOZANTINIB |
Cabometyx® |
IPSEN PTY LTD |
Pancreatic neuroendocrine tumors (pNET) Extra-pancreatic neuroendocrine tumors (epNET) |
Jul 2025 |
Recommended |
| ARIPIPRAZOLE |
Abilify Maintena® |
LUNDBECK AUSTRALIA PTY LTD |
Schizophrenia |
Jul 2025 |
Recommended |
| PEMBROLIZUMAB |
Keytruda® |
MERCK SHARP & DOHME (AUSTRALIA) PTY LTD |
Endometrial cancer |
Jul 2025 |
Not Recommended |
| GLOFITAMAB |
Columvi® |
ROCHE PRODUCTS PTY LTD |
Relapsed or refractory diffuse large B-cell lymphoma |
Jul 2025 |
Recommended |
| INFLIXIMAB |
Remsima® |
CELLTRION HEALTHCARE AUSTRALIA PTY LTD |
Severe active rheumatoid arthritis Ankylosing spondylitis Severe psoriatic arthritis
Severe chronic plaque psoriasis Severe Crohn disease Complex refractory fistulising
Crohn Disease Moderate to severe ulcerative colitis |
Jul 2025 |
Recommended |
| METHADONE |
Methadone-AFT |
AFT PHARMACEUTICALS (AU) PTY LTD |
Chronic severe disabling pain |
Jul 2025 |
Recommended |
| SELADELPAR |
Livdelzi® |
GILEAD SCIENCES PTY LTD |
Primary biliary cholangitis |
Jul 2025 |
Deferred |
| TIRZEPATIDE |
Mounjaro® Mounjaro® KwikPen® |
ELI LILLY AUSTRALIA PTY LTD |
Type 2 diabetes mellitus |
Jul 2025 |
Deferred |
| OSIMERTINIB |
Tagrisso® |
ASTRAZENECA PTY LTD |
Unresectable locally advanced (Stage III) non-small cell lung cancer |
Jul 2025 |
Recommended |
| AFLIBERCEPT |
Afqlir® Enzeevu™ |
SANDOZ PTY LTD |
Macular oedema secondary to retinal vein occlusion (RVO) Diabetic macular oedema (DMO)
Subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration
(AMD) |
Jul 2025 |
Recommended |
| BRENTUXIMAB VEDOTIN |
Adcetris® |
TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD. |
Hodgkin lymphoma |
Jul 2025 |
Recommended |
| ABALOPARATIDE |
Eladynos® |
THERAMEX AUSTRALIA PTY LTD |
Osteoporosis |
Jul 2025 |
Recommended |
| BREXPIPRAZOLE |
Rexulti® |
LUNDBECK AUSTRALIA PTY LTD |
Schizophrenia |
Jul 2025 |
Recommended |
| RIBOCICLIB |
Kisqali® |
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED |
Hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative
(HER2-) early breast cancer |
Jul 2025 |
Not Recommended |
| VELMANASE ALPHA |
Lamzede® |
CHIESI AUSTRALIA PTY LTD |
Alpha- mannosidosis |
Jul 2025 |
Deferred |
| PEGUNIGALSIDASE ALFA |
Elfabrio® |
CHIESI AUSTRALIA PTY LTD |
Fabry disease |
Jul 2025 |
Recommended |
| CANNABIDIOL |
Epidyolex® |
JAZZ PHARMACEUTICALS ANZ PTY LTD |
Seizures of the Lennox-Gastaut syndrome (LGS) |
Jul 2025 |
Recommended |
| MIRVETUXIMAB SORAVTANSINE |
Elahere® |
ABBVIE PTY LTD |
Epithelial ovarian, fallopian tube or primary peritoneal cancer |
Jul 2025 |
Deferred |
| INSULIN DEGLUDEC |
Tresiba® Penfill® |
NOVO NORDISK PHARMACEUTICALS PTY. LIMITED |
Type 1 diabetes mellitus |
Jul 2025 |
Recommended |
| OCRELIZUMAB |
Ocrevus® |
ROCHE PRODUCTS PTY LTD |
Relapsing-remitting multiple sclerosis |
Jul 2025 |
Recommended |
| GUSELKUMAB |
Tremfya® |
JANSSEN-CILAG PTY LTD |
Severe Crohn disease |
Jul 2025 |
Recommended |
| PALIPERIDONE |
Paljuna Monthly |
JUNO PHARMACEUTICALS PTY LTD |
Schizophrenia |
Jul 2025 |
Recommended |
| NIVOLUMAB IPILIMUMAB |
Opdivo® Yervoy® |
BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD |
Advanced (unresectable) Barcelona Clinic Liver Cancer Stage A, Stage B or Stage C
hepatocellular carcinoma |
Jul 2025 |
Not Recommended |
| TACROLIMUS |
aZematop® |
ARROTEX PHARMACEUTICALS PTY LTD |
Atopic dermatitis |
Jul 2025 |
Recommended |
| VORASIDENIB |
Voranigo® |
SERVIER LABORATORIES (AUST.) PTY. LTD. |
Astrocytoma or oligodendroglioma |
Jul 2025 |
Not Recommended |
| GIVOSIRAN |
Givlaari® |
MEDISON PHARMA AUSTRALIA PTY LIMITED |
Acute hepatic porphyria |
Jul 2025 |
Deferred |
| ABIRATERONE AND PREDNISOLONE |
Andriga-10 |
ACTOR PHARMACEUTICALS PTY LTD |
Castration resistant carcinoma of the prostate |
Jul 2025 |
Recommended |
| ENOXAPARIN |
Enoxaject® |
PHARMACOR PTY LIMITED |
Prevention of venous thromboembolism (VTE) Treatment of venous thrombosis Prevention
of extracorporeal thrombosis during haemodialysis Treatment of acute ST-segment elevation
myocardial infarction (STEMI), non-STEMI and unstable angina |
Jul 2025 |
Recommended |
| APOMORPHINE |
Movapo® POD |
STADA PHARMACEUTICALS AUSTRALIA PTY LIMITED |
Parkinson disease |
Jul 2025 |
Recommended |
| PALOPEGTERIPARATIDE |
Yorvipath® |
SPECIALISED THERAPEUTICS PHARMA PTY LTD |
Chronic hypoparathyroidism |
Jul 2025 |
Not Recommended |
| FUTIBATINIB |
Lytgobi® |
TAIHO PHARMA OCEANIA PTY LTD |
Bile duct cancer (cholangiocarcinoma) |
Jul 2025 |
Not Recommended |
| BULEVIRTIDE |
Hepcludex® |
GILEAD SCIENCES PTY LTD |
Chronic hepatitis D |
Jul 2025 |
Recommended |
| ODEVIXIBAT |
Bylvay® |
IPSEN PTY LTD |
Progressive familial intrahepatic cholestasis (PFIC) |
Jul 2025 |
Recommended |
| NIVOLUMAB IPILIMUMAB |
|
BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD |
Unresectable advanced and metastatic cancer |
Jul 2025 |
Deferred |
| PEMBROLIZUMAB |
Keytruda® |
MERCK SHARP & DOHME (AUSTRALIA) PTY LTD |
Unresectable advanced and metastatic cancer |
Jul 2025 |
Not Recommended |
| TORIPALIMAB |
Zytorvi® |
DR REDDY'S LABORATORIES AUSTRALIA PTY LTD |
Nasopharyngeal carcinoma |
Jul 2025 |
Recommended |
| TRIGLYCERIDES, MEDIUM CHAIN |
MCT Oil |
NUTRICIA AUSTRALIA PTY LIMITED |
Chylous ascites Chylothorax Fat malabsorption Hyperlipoproteinaemia type 1 Intractable childhood epilepsy Cerebrospinal fluid glucose transporter defect Long chain fatty acid oxidation disorders |
Jul 2025 |
Recommended |
| TRIGLYCERIDES - MEDIUM CHAIN, FORMULA |
Monogen® |
NUTRICIA AUSTRALIA PTY LIMITED |
Dietary management of conditions requiring a source of medium chain triglycerides Hyperlipoproteinaemia type 1 Long chain fatty acid oxidation disorders Chylous ascites Chylothorax |
Jul 2025 |
Recommended |